Sprint Bioscience
1,44 SEK 0%1 investor følger denne virksomhed
Sprint Bioscience is a research company. The company develops pharmaceutical candidates that alone or in combination with other pharmaceuticals can fight cancer. The company has a project portfolio focused on attacking parts of cancer cell processes. The company's business model is based on developing projects parallel in the preclinical phase to subsequently enter into licensing agreements with the global pharmaceutical industry. The company was founded in 2009 and is headquartered in Huddinge.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
SPRINT
Daglig lav / høj pris
1,294 / 1,444
SEK
Markedsværdi
100,54 mio. SEK
Aktieomsætning
66,4 t SEK
Volumen
49 t
Finanskalender
Delårsrapport
28.08.2024
Delårsrapport
30.10.2024
Årsrapport
12.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
First Venture Sweden | 14,1 % | 14,1 % |
Nordnet Pensionsförsäkring | 10,0 % | 10,0 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Positive preclinical results in Sprint Bioscience's oncology program targeting TREX1
New data from the VPS34 program published
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools